eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2024
vol. 28
 
Share:
Send email
Share:
Original paper

Characteristics and outcomes of patients with lymphoma who developed therapy-related acute myeloid leukemia or myelodysplastic syndrome – a retrospective analysis of the Polish Adult Leukemia Group

Aleksandra Gołos
1
,
Damian Mikulski
2
,
Monika Grobelska-Kowalik
3
,
Krzysztof Mądry
4
,
Karol Lis
4
,
Marta Sobas
5
,
Agnieszka Ożańska
5
,
Magdalena Czemerska
1
,
Dorota Hawrylecka
6
,
Agnieszka Stelmach-Gołdyś
7
,
Karolina Chromik
8
,
Bartosz Puła
9
,
Małgorzata Sobczyk-Kruszelnicka
10
,
Joanna Góra-Tybor
1

  1. Hematology Department, Medical University of Łódź, Łódź, Poland
  2. Department Of Biostatistics And Translational Medicine, Medical University of Łódź, Łódź, Poland
  3. Hematooncology Department, Provincial Multi-Specialized Oncology and Trauma Center, Łódź, Poland
  4. Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
  5. Department and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wrocław Medical University, Wrocław, Poland
  6. Department of Hematology, Hospital Brzozów, Brzozów, Poland
  7. Department of Hematology, Holy Cross Cancer Centre, Kielce, Poland
  8. Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, School of Medicine in Katowice, Katowice, Poland
  9. Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
  10. Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Contemp Oncol (Pozn) 2024; 28 (2): 149–157
DOI: https://doi.org/10.5114/wo.2024.141727
Online publish date: 2024/07/24
Article file
- Characteristics and outcomes (1).pdf  [0.39 MB]
Get citation
 
PlumX metrics:
 
1. Joelsson J, Wasterlid T, Rosenquist R, et al. Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study. Blood Adv 2022; 6: 2657-2666.
2. Fianchi L, Criscuolo M, Fabiani E, et al. Therapy-related myeloid neoplasms: clinical perspectives. Onco Targets Ther 2018; 11: 5909-5915.
3. Al-Juhaishi T, Khurana A, Shafer D. Therapy-related myeloid neoplasms in lymphoma survivors: reducing risks. Best Pract Res Clin Haematol 2019; 32: 47-53.
4. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
5. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-405.
6. Borthakur G, Estey AE. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome. Curr Oncol Rep 2007; 9: 373-377.
7. Greim H, Kaden DA, Larson RA, et al. The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment. Ann N Y Acad Sci 2014; 1310: 7-31.
8. Gertz MA, Terpos E, Dispenzieri A, et al. Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. Leuk Lymphoma 2015; 56: 1723-1726.
9. Greene MH, Young RC, Merrill JM, DeVita VT. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin’s lymphoma. Cancer Res 1983; 43: 1891-1898.
10. Morton LM, Curtis RE, Linet MS, et al. Second malignancy risks after non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 2010; 28: 4935-4944.
11. Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients. J Clin Oncol 2003; 21: 897-906.
12. Rosner F, Grunwald H. Multiple myeloma terminating in acute leukemia. Report of 12 cases and review of the literature. Am J Med 1974; 57: 927-939.
13. Govindarajan R, Jagannath S, Flick JT, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996; 95: 349-353.
14. Fenk R, Neubauer F, Bruns I, et al. Secondary primary malignancies in patients with multiple myeloma treated with high-dose chemotherapy and autologous blood stem cell transplantation. Br J Haematol 2012; 156: 683-686.
15. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770-1781.
16. Attal M, Cances Lauwers V, Marit G, et al. Maintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005-02. Blood 2010; 116: 310.
17. Jones JR, Cairns DA, Menzies T, et al. Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial. EClinicalMedicine 2023; 62: 102099.
18. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454-2465.
19. Estey EH. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 2013; 88: 317-327.
20. Budczies J, Klauschen F, Sinn BV, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomar- ker cutoff optimization. PLoS One 2012; 7: e51862.
21. Bertoli S, Sterin A, Tavitian S, et al. Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies. Oncotarget 2016; 7: 85937-85947.
22. Maung SW, Burke C, Hayde J, et al. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience. Hematology 2017; 22: 341-346.
23. Puertas B, González-Calle V, Sobejano-Fuertes E, et al. Novel agents as main drivers for continued improvement in survival in multiple myeloma. Cancers 2023; 15: 1558.
24. Sahebi F, Iacobelli S, Sbianchi G, et al. Incidence of second primary malignancies after autologous transplantation for multiple myeloma in the era of novel agents. Biol Blood Marrow Transplant 2018; 24: 930-936.
25. Wang J, Lv C, Zhou M, et al. Second primary malignancy risk in multiple myeloma from 1975 to 2018. Cancers 2022; 14: 4919.
26. Pemmaraju N, Shah D, Kantarjian H, et al. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2015; 15: 110-114.
27. Larson RA. Therapy-related myeloid neoplasms. Haematologica 2009; 94: 454-459.
28. Larson RA. Cytogenetics, not just previous therapy, determines the course of therapy-related myeloid neoplasms. J Clin Oncol 2012; 30: 2300-2302.
29. Adamska M, Kowal-Wisniewska E, Przybylowicz-Chalecka A, et al. Clinical outcomes of therapy-related acute myeloid leukemia: an over 20-year single-center retrospective analysis. Pol Arch Intern Med 2023; 133: 16344.
30. Litzow MR, Tarima S, Perez WS, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010; 115: 1850-1857.
31. Koontz MZ, Horning SJ, Fau-Balise R, et al. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol 2013; 31: 592-598.
32. Valagussa P, Santoro A, Fossati Bellani F, et al. Absence of treatment-induced second neoplasms after ABVD in Hodgkin’s disease. Blood 1982; 59: 488-494.
33. Brusamolino E, Anselmo AP, Klersy C, et al. The risk of acute leukemia in patients treated for Hodgkin’s disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Haematologica 1998; 83: 812-823.
34. Pedersen-Bjergaard J. Insights into leukemogenesis from therapy- related leukemia. N Engl J Med 2005; 352: 1591-1594.
35. Ornstein MC, Mukherjee S, Mohan S, et al. Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia. Am J Hematol 2014; 89: 168-173.
36. Hake CR, Graubert TA, Fenske TS. Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? Bone Marrow Transplant 2007; 39: 59-70.
37. Milligan DW, Ruiz De Elvira MC, Kolb HJ, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol 1999; 106: 1020-1026.
38. Fianchi L, Pagano L, Piciocchi A, et al. Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. Am J Hematol 2015; 90: E80-5.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.